Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Expected to Post Q3 2024 Earnings of ($0.44) Per Share

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Stock analysts at Leerink Partnrs lifted their Q3 2024 earnings estimates for Fulcrum Therapeutics in a note issued to investors on Wednesday, July 31st. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.44) per share for the quarter, up from their prior forecast of ($0.46). The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($1.24) per share. Leerink Partnrs also issued estimates for Fulcrum Therapeutics’ Q4 2024 earnings at ($0.44) EPS, FY2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.47) EPS and FY2025 earnings at ($1.82) EPS.

A number of other brokerages also recently issued reports on FULC. Cantor Fitzgerald reiterated an “overweight” rating and set a $23.00 price target on shares of Fulcrum Therapeutics in a research report on Wednesday, July 10th. The Goldman Sachs Group upgraded Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $6.00 to $15.00 in a research report on Monday, May 13th. HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Fulcrum Therapeutics in a research note on Thursday, August 1st. Finally, Oppenheimer cut their price objective on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Tuesday, May 14th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $15.57.

Fulcrum Therapeutics Trading Up 4.8 %

Shares of FULC stock opened at $8.87 on Monday. The firm’s 50 day moving average is $7.60 and its 200 day moving average is $8.24. The stock has a market capitalization of $553.49 million, a P/E ratio of -5.57 and a beta of 2.29. Fulcrum Therapeutics has a 12 month low of $3.14 and a 12 month high of $13.70.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.01. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 8.28%.

Institutional Trading of Fulcrum Therapeutics

A number of institutional investors have recently modified their holdings of the company. Vestal Point Capital LP bought a new position in Fulcrum Therapeutics during the 4th quarter valued at approximately $6,919,000. ADAR1 Capital Management LLC purchased a new stake in Fulcrum Therapeutics in the fourth quarter worth $4,302,000. Assenagon Asset Management S.A. purchased a new stake in Fulcrum Therapeutics in the second quarter worth $3,084,000. abrdn plc bought a new stake in Fulcrum Therapeutics in the fourth quarter valued at $1,734,000. Finally, Mass General Brigham Inc purchased a new position in Fulcrum Therapeutics during the 1st quarter valued at $1,939,000. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.